The estimated Net Worth of Nippon Biomedical Laborator... is at least $9.27 millió dollars as of 6 June 2023. Nippon Laborator owns over 30,477,313 units of Satsuma Pharmaceuticals stock worth over $9,266,105 and over the last few years Nippon sold STSA stock worth over $0.
Nippon has made over 1 trades of the Satsuma Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently Nippon bought 30,477,313 units of STSA stock worth $27,734,355 on 6 June 2023.
The largest trade Nippon's ever made was buying 30,477,313 units of Satsuma Pharmaceuticals stock on 6 June 2023 worth over $27,734,355. On average, Nippon trades about 30,477,313 units every 0 days since 2023. As of 6 June 2023 Nippon still owns at least 8,423,732 units of Satsuma Pharmaceuticals stock.
You can see the complete history of Nippon Laborator stock trades at the bottom of the page.
Nippon's mailing address filed with the SEC is 2438 MIYANOURA-CHO, , KAGOSHIMA-SHI, M0, 891-1394.
Over the last 5 years, insiders at Satsuma Pharmaceuticals have traded over $2,307,500 worth of Satsuma Pharmaceuticals stock and bought 63,855,812 units worth $106,923,937 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Capital Management, L.P.Ra ... és Nippon Biomedical Laborator.... On average, Satsuma Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $2,050,940. The most recent stock trade was executed by Ken Takanashi on 6 June 2023, trading 22,053,581 units of STSA stock currently worth $20,068,759.
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Satsuma Pharmaceuticals executives and other stock owners filed with the SEC include: